NICE technology appraisal guidance
Issued: April 2012
TA251

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70)

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta251

1 Guidance

This guidance should be read in conjunction with the following NICE guidance: NICE technology appraisal guidance 70 (TA70) Guidance on the use of imatinib for chronic myeloid leukaemia.

This guidance partially updates NICE technology appraisal guidance 70 (published October 2003).

For details see About this guidance.

1.1 Standard-dose imatinib[1] is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia (CML).

1.2 Nilotinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive CML if the manufacturer makes nilotinib available with the discount agreed as part of the patient access scheme.

1.3 Dasatinib is not recommended for the first-line treatment of chronic phase Philadelphia-chromosome-positive CML.

1.4 People currently receiving dasatinib that is not recommended according to 1.3 should be able to continue treatment until they and their clinician consider it appropriate to stop.



[1] The summary of product characteristics (SPC) for imatinib states that the recommended dosage of imatinib is 400 mg per day for patients in chronic phase CML.